Quality indicator set for systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 29, Issue 2 SUPPL. 65, 2011, Pages

  Khanna, Dinesh ^a   Kowal Bielecka, O ^c   Khanna, P P ^a   Lapinska, A ^c   Asch, S M ^a,b   Wenger, N ^a   Brown, K K ^d   Clements, P ^a   Getzug, T ^a   Mayes, M D ^e   Medsger Jr , T A ^f   Oudiz, R ^g   Simms, R ^h   Steen, V ⁱ   Maranian, P ^a   Furst, D E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d DEPARTMENT OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g HARBOR UCLA MEDICAL CENTER   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Quality indicator; Systemic sclerosis

Indexed keywords

ARTICLE; CLINICAL RESEARCH; EXPERT SYSTEM; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; VALIDATION STUDY; BLOOD PRESSURE MONITORING; BODY MASS; BODY WEIGHT; CARDIOMYOPATHY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIASTOLIC DYSFUNCTION; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROMYOGRAPHY; FINGER ULCER; FORCED VITAL CAPACITY; FUNCTIONAL STATUS ASSESSMENT; GASTROESOPHAGEAL REFLUX; HEART FAILURE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; INFLUENZA; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MALABSORPTION; MUSCLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDIAL EFFUSION; PNEUMOCOCCAL INFECTION; PULMONARY HYPERTENSION; SCLERODERMA; SKINFOLD THICKNESS; SPIROMETRY;

ADVISORY COMMITTEES; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); POLICY MAKING; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; SCLERODERMA, SYSTEMIC;

ANTACID AGENT; AUTOANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTROMERE ANTIBODY; CREATINE KINASE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; HEMOGLOBIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; NITRATE; PHOSPHODIESTERASE V INHIBITOR; PNEUMOCOCCUS VACCINE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTON PUMP INHIBITOR; RNA POLYMERASE III ANTIBODY; TOPOISOMERASE I ANTIBODY; UNCLASSIFIED DRUG;

EID: 79960400051     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. ALTMAN RD, MEDSGER TA, JR., BLOCH DA, MICHEL BA: Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-13.
2. BERNATSKY S, HUDSON M, PANOPALIS P et al.: The cost of systemic sclerosis. Arthritis Rheum 2009; 61: 119-23.
3. WIGLEY FM, LIMA JA, MAYES M, MCLAIN D, CHAPIN JL, WARD-ABLE C: The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52: 2125-32.
4. KHANNA D, YAN X, TASHKIN DP et al.: Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study. Arthritis Rheum 2007; 56: 1676-84.
5. KHANNA D, HAYS RD, MARANIAN P et al.: Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009; 61: 1257-63.
6. MACLEAN CH, SAAG KG, SOLOMON DH, MORTON SC, SAMPSEL S, KLIPPEL JH: Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum 2004; 51: 193-202.
7. MIKULS TR, MACLEAN CH, OLlVIERI J et al.: Quality of care indicators for gout management. Arthritis Rheum 2004; 50: 937-43.
8. SAAG KG, OLIVIERI JJ, PATINO F, MIKULS TR, ALLISON JJ, MACLEAN CH: Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics. Arthritis Rheum 2004; 51: 337-49.
9. YAZDANY J, PANOPALIS P, GILLIS JZ et al.: A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 2009; 61: 370-7.
10. KHANNA D, ARNOLD EL, PENCHARZ JN et al.: Measuring process of arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritis. Semin Arthritis Rheum 2006; 35: 211-37.
11. AVOUAC J, KOWAL-BIELECKA O, LANDEWÉ R et al.: European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis 2009; 68: 629-34.
12. BROOK RH, MCGLYNN EA, SHEKELLE PG: Defining and measuring quality of care: a perspective from US researchers. Int J Qual Health Care 2000; 12: 281-95.
13. BROOK R: The RAND/UCLA Appropriateness Method. Methodology Perspectives, AHCPR no. 95-0009, Rockville, Md., Public Health Service, pp. 59-70. 1994.
14. SOLOMON DH, GABRIEL SE: Moving forward with quality: pay for reporting meets rheumatology. Arthritis Rheum 2007; 57: 703-4.
15. KHANNA D, BROWN A: Quality of Care for Veterans Diagnosed with Rheumatoid Arthritis [abstract]. Arthritis Rheum 2007; 56: S112.
16. HACHULLA E, GRESSIN V, GUILLEVIN L et al.: Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-800.
17. McGOON M, GUTTERMAN D, STEEN V et al.: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(1 Suppl.): 14S-34S.
18. KOWAL-BIELECKA O, LANDEWÉ R, AVOUAC J et al.: EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-8.